Cargando…
Proteasome impairment in neural cells derived from HMSN-P patient iPSCs
Hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) is caused by a heterozygous mutation (P285L) in Tropomyosin-receptor kinase Fused Gene (TFG), histopathologically characterized by progressive spinal motor neuron loss with TFG cytosolic aggregates. Although the TFG...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310050/ https://www.ncbi.nlm.nih.gov/pubmed/28196470 http://dx.doi.org/10.1186/s13041-017-0286-y |
_version_ | 1782507809359790080 |
---|---|
author | Murakami, Nagahisa Imamura, Keiko Izumi, Yuishin Egawa, Naohiro Tsukita, Kayoko Enami, Takako Yamamoto, Takuya Kawarai, Toshitaka Kaji, Ryuji Inoue, Haruhisa |
author_facet | Murakami, Nagahisa Imamura, Keiko Izumi, Yuishin Egawa, Naohiro Tsukita, Kayoko Enami, Takako Yamamoto, Takuya Kawarai, Toshitaka Kaji, Ryuji Inoue, Haruhisa |
author_sort | Murakami, Nagahisa |
collection | PubMed |
description | Hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) is caused by a heterozygous mutation (P285L) in Tropomyosin-receptor kinase Fused Gene (TFG), histopathologically characterized by progressive spinal motor neuron loss with TFG cytosolic aggregates. Although the TFG protein, found as a type of fusion oncoprotein, is known to facilitate vesicle transport from endoplasmic reticulum (ER) to Golgi apparatus at ER exit site, it is unclear how mutant TFG causes motor neuron degeneration. Here we generated induced pluripotent stem cells (iPSCs) from HMSN-P patients, and differentiated the iPSCs into neural cells with spinal motor neurons (iPS-MNs). We found that HMSN-P patient iPS-MNs exhibited ubiquitin proteasome system (UPS) impairment, and HMSN-P patient iPS-MNs were vulnerable to UPS inhibitory stress. Gene correction of the mutation in TFG using the CRISPR-Cas9 system reverted the cellular phenotypes of HMSN-P patient iPS-MNs. Collectively, these results suggest that our cellular model with defects in cellular integrity including UPS impairments may lead to identification of pathomechanisms and a therapeutic target for HMSN-P. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13041-017-0286-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5310050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53100502017-03-13 Proteasome impairment in neural cells derived from HMSN-P patient iPSCs Murakami, Nagahisa Imamura, Keiko Izumi, Yuishin Egawa, Naohiro Tsukita, Kayoko Enami, Takako Yamamoto, Takuya Kawarai, Toshitaka Kaji, Ryuji Inoue, Haruhisa Mol Brain Research Hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) is caused by a heterozygous mutation (P285L) in Tropomyosin-receptor kinase Fused Gene (TFG), histopathologically characterized by progressive spinal motor neuron loss with TFG cytosolic aggregates. Although the TFG protein, found as a type of fusion oncoprotein, is known to facilitate vesicle transport from endoplasmic reticulum (ER) to Golgi apparatus at ER exit site, it is unclear how mutant TFG causes motor neuron degeneration. Here we generated induced pluripotent stem cells (iPSCs) from HMSN-P patients, and differentiated the iPSCs into neural cells with spinal motor neurons (iPS-MNs). We found that HMSN-P patient iPS-MNs exhibited ubiquitin proteasome system (UPS) impairment, and HMSN-P patient iPS-MNs were vulnerable to UPS inhibitory stress. Gene correction of the mutation in TFG using the CRISPR-Cas9 system reverted the cellular phenotypes of HMSN-P patient iPS-MNs. Collectively, these results suggest that our cellular model with defects in cellular integrity including UPS impairments may lead to identification of pathomechanisms and a therapeutic target for HMSN-P. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13041-017-0286-y) contains supplementary material, which is available to authorized users. BioMed Central 2017-02-15 /pmc/articles/PMC5310050/ /pubmed/28196470 http://dx.doi.org/10.1186/s13041-017-0286-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Murakami, Nagahisa Imamura, Keiko Izumi, Yuishin Egawa, Naohiro Tsukita, Kayoko Enami, Takako Yamamoto, Takuya Kawarai, Toshitaka Kaji, Ryuji Inoue, Haruhisa Proteasome impairment in neural cells derived from HMSN-P patient iPSCs |
title | Proteasome impairment in neural cells derived from HMSN-P patient iPSCs |
title_full | Proteasome impairment in neural cells derived from HMSN-P patient iPSCs |
title_fullStr | Proteasome impairment in neural cells derived from HMSN-P patient iPSCs |
title_full_unstemmed | Proteasome impairment in neural cells derived from HMSN-P patient iPSCs |
title_short | Proteasome impairment in neural cells derived from HMSN-P patient iPSCs |
title_sort | proteasome impairment in neural cells derived from hmsn-p patient ipscs |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310050/ https://www.ncbi.nlm.nih.gov/pubmed/28196470 http://dx.doi.org/10.1186/s13041-017-0286-y |
work_keys_str_mv | AT murakaminagahisa proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs AT imamurakeiko proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs AT izumiyuishin proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs AT egawanaohiro proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs AT tsukitakayoko proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs AT enamitakako proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs AT yamamototakuya proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs AT kawaraitoshitaka proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs AT kajiryuji proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs AT inoueharuhisa proteasomeimpairmentinneuralcellsderivedfromhmsnppatientipscs |